Skip to main content

Illumigen Assembles All-Star Bioinformatics Team to Build Drug Discovery Platform


Startup Illumigen Biosciences has enlisted the help of some leading bioinformaticists to build a computational analysis platform for its in-house drug discovery efforts.

Founded by researchers from the University of Washington’s Genome Center, Illumigen’s scientific/medical advisory board is chaired by UWGC director Maynard Olson. Phil Green, who authored the Phred/Phrap/Consed integrated base-calling and sequence-assembly system, is also on the advisory board.

The GeneLamp platform will seek out information from a variety of databases that is complementary to three proprietary patient populations to which the company has exclusive access.

“In many ways I think I can say that this company is bioinformatics driven,” said Hugh MacNaught, Illumigen CEO. He said that the first version would be completed by June and will be used to support Illumigen’s proprietary discovery efforts.

The next step, MacNaught said, would be to supply the platform along with new modules to selected collaborators. Although he said the company would consider a shrink-wrapped product as the final stage, he added, “I have not really seen a sustainable business model for bioinformatics, so the jury’s still out on whether we go to that third step or not.”

Others in the industry have also questioned the long-term sustainability of the bioinformatics-vendor model.

“I believe that a new order in IT outsourcing and scientific consulting is about to emerge, and the current publicly held [bioinformatics] firms will be struggling to keep up,” said Eric Neumann, vice president of life science informatics at bioinformatics consultancy 3rd Millennium.

Seattle, Wash.-based Illumigen, which aims to find host-resistance genes through genomics technology, recently closed a $3 million financing round led by Pacific Horizon Ventures, also in Seattle, and is looking to raise another $2 million by the end of February.

The company will first focus on identifying targets for hepatitis C. MacNaught estimated that Illumigen would reach the drug development stage within two years.

— BT

Filed under

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.